Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)

Summary

Valemetostat tosylate demonstrates antitumour activity in patients with peripheral T-cell lymphomas (PTCL) with a manageable safety profile. This Medical Access Program (MAP) offers an alternative treatment option for patients with PTCL who are ineligible for clinical trials by providing access to valmetostat tosylate, a medicinal product that has received marketing authorisation in Japan.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications